NASTAD’s Post

🌟 Revolutionizing HIV Prevention in Kenya! 🌟 A groundbreaking urine-based assay is transforming how Kenyan women on pre-exposure prophylaxis (PrEP) monitor their HIV prevention efforts! 💡 Key Highlights: - Real-Time Feedback: This innovative test provides immediate insights into adherence, empowering users and healthcare providers alike. - Positive Reception: Participants praise its accuracy, while healthcare professionals note enhanced counseling and stronger patient relationships. - Addressing Challenges: Despite its promise, concerns about stigma and accessibility must be tackled to ensure widespread implementation. Integrating this assay into standard PrEP programs could significantly boost adherence rates and support women at risk of HIV. Let's champion ongoing education and community engagement to promote acceptance of this vital tool! 🔗 Click the link for more details on this transformative development! #ClinicalResearches #HIVPrevention #HealthcareInnovation #Kenya #Pharma #PrEP #WomenEmpowerment #MarketAccess #MarketAccessToday

🚨 HIV Drug Access: Challenges Persist Despite Promising Innovations 🚨 New advancements in HIV prevention and treatment, such as lenacapavir and long-acting cabotegravir, offer hope to transform care. Yet, access barriers remain critical, especially in low- and middle-income countries (LMICs). 🔑 Key Takeaways: 🔘 Access Gap: Licensing for new drugs excludes key regions, such as parts of Latin America, despite their participation in trials. 🔘 Key Populations at Risk: Discrimination and criminalization severely impact young men, transgender women, and other vulnerable groups. 🔘 Systemic Hurdles: Weak health systems and limited funding slow the adoption of life-saving innovations. 🔘 Call to Action: Advocating for global equity, stronger health systems, and the decriminalization of at-risk groups is essential to progress. ✨ The Way Forward: Progress in HIV care isn't just about new drugs but ensuring they reach those who need them most. #HIVPrevention #HealthEquity #GlobalHealth #HIVCare #OneHealth #AIDSResponse #InnovationForAll

Providers and health systems have an essential role in #EndingtheHIVEpidemic. In the most recent post on the Journal of Clinical Pathways blog, my coauthors and I discuss a new #ImprovementActivity included in CMS' Merit-based Incentive Payment System (MIPS) and share how providers can enhance their #HIVprevention efforts in line with CMS' #valuebasedcare initiatives.

💎 Read latest scientific findings of prevention technologies for girls and women presented at the ongoing #HIVR4P (HIV Research For Prevention Conference of International AIDS Society): a lot of new HIV prevention tools are at very advanced stage of scientific R&D pipeline or regulatory processes or introduction in near future. #MyBodyMyChoice: The importance of choice and access in combating the HIV epidemic was the dominant theme of HIVR4P in #Lima, #Peru. Thanks to researchers like Jeremy Nuttall of Population Council, Dr Melissa Peet of CONRAD/ Eastern Virginia Medical School, researchers of University of Pittsburgh School of Medicine Magee-Womens Research Institute & Foundation UPMC among others for helping #MAKEaDIFFERENCE! CNS Managing Editor Shobha Shukla ✍️ https://lnkd.in/gG-7Skiq #HIV #AIDS #endAIDS #preventionresearch #PreventionIsBetterThanCure #prevention #infectionprevention #diseaseprevention #HIVR4PPeru #HIVR4PLima #healthresearch #healthjournalism #sciencejournalism #HIVscience

🌍 Exciting Progress in HIV Prevention! But more need to be done🌍 The recent announcement at the International AIDS Conference about the extraordinary results from Gilead’s PURPOSE 1 trial is a significant milestone. The trial demonstrated 100% efficacy of *Lenacapavir* in preventing new HIV infections among cisgender women and adolescent girls. This twice-yearly injectable is a game-changer, especially for vulnerable populations in sub-Saharan Africa. However, while this is a monumental step forward, more needs to be done. Unitaid’s call for accelerated global access to Lenacapavir is crucial. We must ensure that: 🏛️ Regulatory steps are expedited 💰 Pricing is fair and accessible 🏭 Production planning is efficient 🧬 Support for generic development is robust 🌐 Transparency and equity in access strategies are prioritized We must work to make this life-saving innovation accessible to all who need it, regardless of where they live. The fight against HIV is far from over, and we must continue to push for comprehensive, inclusive solutions. Read more here : https://lnkd.in/eH8BgtYn #HIVPrevention #SRHR #GlobalHealth #Lenacapavir #Unitaid #HealthEquity #HIV

The global decline in new HIV infections highlights the power of innovative prevention technologies. However, infections remain high among high-risk populations, pointing to gaps in accessibility and affordability. Gilead’s recent licensing of six generic manufacturers to produce lenacapavir—a twice-yearly injectable for HIV prevention and treatment—marks a positive step. Yet, as highlighted in The BMJ, further efforts could increase access, including strengthening local manufacturing, particularly where clinical trials have been conducted and in countries with the highest HIV burden. Linking trial sites to manufacturing hubs could help build self-sufficiency in essential health supplies. True impact will come when these technologies are not only accessible and affordable but also integrated into health systems that address the social barriers driving new infections. Real progress lies in pairing innovation with inclusive, community-driven approaches to deliver prevention tools to those who need them most.

Introduction by Croakey: The 25th International AIDS Conference is taking place this week in Munich, Germany, with the theme ‘putting people first’. Conference organisers explain that this means thinking of solutions from the point of view of those most affected. “For example, rather than thinking of hard-to-reach populations, we should think of hard-to-reach health services. HIV responses must be built for the individual, especially the most vulnerable,” they say. Meanwhile, researchers from the Kirby Institute at UNSW Sydney have outlined reforms that would enable more equitable access to an important element of HIV prevention, Pre-exposure prophylaxis, or PrEP. Their recommendations, which include measures to ensure cheaper, easier access to PrEP, are timely as the national Scope of Practice Review develops recommendations aimed at ensuring more equitable access to primary care.

📃Scientific paper: Impact of COVID-19 on Adolescent HIV Prevention and Treatment Services in the AHISA Network Abstract: We investigated perceived impacts of COVID-19 on the delivery of adolescent HIV treatment and prevention services in sub-Saharan Africa (SSA) by administering a survey to members of the Adolescent HIV Prevention and Treatment Implementation Science Alliance (AHISA) from February to April 2021. We organized COVID-19 impacts, as perceived by AHISA teams, under three themes: service interruptions, service adjustments, and perceived individual-level health impacts. AHISA teams commonly reported interruptions to prevention programs, diagnostic testing, and access to antiretroviral therapy (ART). Common service adjustments included decentralization of ART refills, expanded multi-month ART distribution, and digital technology use. Perceived individual-level impacts included social isolation, loss to follow-up, food insecurity, poverty, and increases in adolescent pregnancies and sexually transmitted infections. The need for collaboration among stakeholders were commonly cited as lessons learned by AHISA teams. Survey findings highlight the need for implementation science research to evaluate the effects of pandemic-related HIV service adaptations in SSA. Continued on ES/IODE ➡️ https://etcse.fr/igL ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.